TScan Therapeutics Files Q2 2024 10-Q
Ticker: TCRX · Form: 10-Q · Filed: 2024-08-12T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
**TScan Therapeutics Q2 2024 10-Q filed. Financials and operations updated.**
AI Summary
TScan Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial data and operational highlights are detailed within the filing, including information on its collaborations and licensing revenue.
Why It Matters
This filing provides investors with the latest financial health and operational status of TScan Therapeutics, crucial for understanding its ongoing development and market position.
Risk Assessment
Risk Level: medium — As a biotechnology company, TScan Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20240812 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- Amgen Inc. (company) — Mentioned in relation to an agreement
- K2 Health Ventures (company) — Mentioned in relation to a tranche
FAQ
What was the total revenue for TScan Therapeutics in the reported period?
The filing indicates collaboration and license revenue, but specific total revenue figures for the period ending June 30, 2024, are not explicitly stated in the provided text snippet.
What is the primary business of TScan Therapeutics?
TScan Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When was TScan Therapeutics incorporated?
The state of incorporation for TScan Therapeutics is Delaware (DE).
Are there any significant agreements mentioned in the filing?
Yes, the filing mentions an 'Amgen Agreement' with 'Amgen Inc.', and a 'TrancheThree' related to 'K2 Health Ventures'.
What is the fiscal year end for TScan Therapeutics?
The fiscal year end for TScan Therapeutics is December 31 (1231).
From the Filing
0000950170-24-095066.txt : 20240812 0000950170-24-095066.hdr.sgml : 20240812 20240812073021 ACCESSION NUMBER: 0000950170-24-095066 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240812 DATE AS OF CHANGE: 20240812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 241194751 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 tcrx-20240630.htm 10-Q 10-Q false --12-31 0001783328 Q2 http://www.tscan.com/20240630#CollaborationAndLicenseRevenue http://www.tscan.com/20240630#CollaborationAndLicenseRevenue http://www.tscan.com/20240630#CollaborationAndLicenseRevenue http://www.tscan.com/20240630#CollaborationAndLicenseRevenue March 31 2020 0001783328 us-gaap:CommonStockMember tcrx:VotingCommonStockMember 2023-12-31 0001783328 2024-04-24 2024-04-24 0001783328 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001783328 tcrx:AmgenAgreementMember tcrx:AmgenIncMember 2024-04-01 2024-06-30 0001783328 tcrx:VotingCommonStockMember us-gaap:IPOMember 2023-06-01 0001783328 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001783328 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001783328 us-gaap:CommonStockMember tcrx:VotingCommonStockMember 2024-03-31 0001783328 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001783328 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-06-30 0001783328 tcrx:K2HealthVenturesMember tcrx:TrancheThreeMember 2022-09-09 0001783328 us-gaap:NonvotingCommonStockMember 2024-06-30 0001783328 tcrx:K2HealthVenturesMember us-gaap:PrimeRateMember 2022-09-09 2022-09-09 0001783328 us-gaap:RetainedEarningsMember 2022-12-31 0001783328 tcrx:VotingCommonStockMember 2024-06-30 0001783328 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001783328 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001783328 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001783328 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2024-06-30 0001783328 tcrx:AmgenAgreementMember tcrx:AmgenIncMember 2023-04-01 2023-06-30 0001783328 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001783328 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001783328 tcrx:K2HealthVenturesMember 2022-09-09 2022-09-09 0001783328 tcrx:AmgenAgreementMember tcrx:AmgenIncMember 2023-07-01 2023-07-31 0001783328 tcrx:VotingCommonStockMember 2024-08-08 0001783328 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001783328 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2023-03-31 0001783328 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001783328 us-gaap:CommonStockMember tcrx:VotingCommonStockMember 2024-01-01 2024-06-30 0001783328 us-gaap:RetainedEarningsMember 2024-06-30 0001783328 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001783328 tcrx:VotingCommonStockMember tcrx:FollowOnOfferingMember 2024-04-24 2024-04-24 0001783328 tcrx:EmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001783328 tcrx:VotingCommonStockMember tcrx:PreFundedWarrantsMember 2023-06-01 2023-06-01 0001783328 us-gaap:MoneyMarketFundsMember 2023-12-31 0001783328 2023-03-31 0001783328 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001783328 us-gaap:USGovernmentDebtSecuritiesMember 2023-12-31 0001783328 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001783328 tcrx:K2HealthVenturesMember 2024-01-01 2024-06-30 0001783328 us-gaap:Add